Advanced Fibrosis Detection for MASLD in Primary Care
Recruiting
N/A
Interventional Study
Metabolic Dysfunction-associated Steatotic Liver Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Health Services Research
- Participants needed
- 225 (estimated)
- Sponsor
- Medical University of South Carolina · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients
Inclusion Criteria:
* Patients with a diagnosis code for MASLD
* Type 2 diabetes mellitus will
Exclusion Criteria:
* All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be…
Contacts